scholarly journals Impact of sample collection method for EGFR mutation testing: results of Blood-based and Tissue-based Cobasâ® EGFR mutation testing in the treatment of locally advanced or metastatic NSCLC in the US

2015 ◽  
Vol 18 (3) ◽  
pp. A41-A42
Author(s):  
N. Poulios ◽  
D. Hristova-Neeley ◽  
M. Gavaghan
Keyword(s):  
Egfr Mutation ◽  
Locally Advanced ◽  
Mutation Testing ◽  
Sample Collection ◽  
Collection Method ◽  
Metastatic Nsclc ◽  
The Us ◽  
Egfr Mutation Testing

scholarly journals 1403P EGFR-mutation testing and TKI treatment patterns in locally advanced or metastatic NSCLC in Norway: A nationwide cohort study

2020 ◽  
Vol 31 ◽  
pp. S889
Author(s):  
Å. Helland ◽  
K.K. Andersen ◽  
T.Å. Myklebust ◽  
T.B. Johannesen ◽  
T. Hallerbäck ◽  
...  
Keyword(s):  
Cohort Study ◽  
Egfr Mutation ◽  
Locally Advanced ◽  
Mutation Testing ◽  
Treatment Patterns ◽  
Metastatic Nsclc ◽  
Tki Treatment ◽  
Egfr Mutation Testing

scholarly journals Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Rhian Siân Davies ◽  
Christian Smith ◽  
Gwenllian Edwards ◽  
Rachel Butler ◽  
Diane Parry ◽  
...  
Keyword(s):  
Egfr Mutation ◽  
Growth Factor Receptor ◽  
Genetic Alterations ◽  
Mutation Testing ◽  
Sample Collection ◽  
Single Institution ◽  
Mutation Status ◽  
Tumour Sample ◽  
Epidermal Growth ◽  
Egfr Mutation Testing

Objectives. There have been advances in the identification and understanding of molecular subsets of lung cancer, defined by specific oncogenic aberrations. A number of actionable genetic alterations have been identified, such as the epidermal growth factor receptor (EGFR) mutation. We aimed to establish the reasons why patients were not undergoing EGFR mutation testing at the time of histological diagnosis. Methods. The records of 70 patients with advanced adenocarcinoma of the lung managed through a single multidisciplinary team at a single institution were reviewed. Data were collected on method of tumour sample collection, whether this was sent for EGFR testing, and the result. Results. Seventy patients were identified. In 21/25 (84%) cases, cytological sampling was sufficient for EGFR mutation analysis, compared with 40/45 (89%) cases with histological sampling. EGFR mutation testing was not carried out in 22/70 (31.4%) patients. There was insufficient tumour sample for EGFR testing in 9/22 (40.9%) patients. Other reasons for not testing included poor patient fitness and problems in the diagnostic pathway. Conclusions. In this series, cytological tumour sampling was not the predominant reason why cancers failed to have EGFR mutation status established.

Prevalence of EGFR mutation testing in early-stage lung cancer: Implications of the ADAURA trial for clinical practice.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e20507-e20507
Author(s):  
Estelamari Rodriguez ◽  
Richa Dawar ◽  
Fahmin Basher ◽  
Philippos Apolinario Costa ◽  
Tisdrey Torres ◽  
...  
Keyword(s):  
Egfr Mutation ◽  
Early Stage ◽  
Disease Free Survival ◽  
Mutation Testing ◽  
Egfr Mutations ◽  
Early Stage Lung Cancer ◽  
Free Survival ◽  
Stage Ib ◽  
Egfr Mutation Testing

e20507 Background: It is reported that about 20% of patients with resected NSCLC adenocarcinoma harbor an EGFR driver mutation in the United States. Up to the recent approval of osimertinib in the adjuvant setting for resected EGFR + NSCLC based on the ADAURA trial, routine molecular profiling of early-stage lung cancer had not been standard of care. We hypothesize that there is a significant proportion of patients with resected adenocarcinoma with unknown EGFR status who could benefit from treatment that are missed with our current testing practices. Methods: We performed a retrospective analysis of Stage IB-IIIA lung adenocarcinomas resected at the University of Miami from 2014 to 2019. Eligible patients were identified from the Cancer Registry and information on EGFR mutation testing and treatment was obtained from chart review. We evaluated the prevalence of EGFR mutation testing in this population and outcomes based on EGFR mutation status. Disease free survival (DFS) and clinico-pathologic characteristics were evaluated. We estimated the number of patients that would have been eligible for EGFR testing and adjuvant osimertinib therapy in the pre-ADAURA era in our patient cohort. Results: A total of 120 patients had resected stage IB-IIIA adenocarcinoma during this five-year period (Stage IB 42.5%; Stage IIA 13.3%; Stage IIB 25%; Stage IIIA 19.2%) with a median age of 66 years. Most were females (59%), NHWs (51.5%), Hispanics (46.9%), and former smokers (66.7%). Out of patients with Stage IB-IIIA NSCLC with adenocarcinoma, 42.5% completed recommended adjuvant platinum-based chemotherapy. Only 40% of patients were referred for EGFR testing during this study period. The prevalence of EGFR mutations in this population was 10.8% (13 /120), but 59% of cases had no available EGFR testing. The most prevalent mutation was L858R (53.8%) followed by exon-19 deletions (30.8%). A total of 6 patients received an EGFR TKI therapy during the follow up period (2 in the adjuvant setting). With a median follow up of 12 mos, the rate of recurrence by stage was: Stage IB (3.9%); Stage IIB (10%); Stage IIIA (13%). Median time to disease progression or death was 13 months in this subgroup. There was no difference in disease free survival for patients with EGFR testing and those without results available in this short follow up period. Conclusions: Based on this retrospective review, up to 60% of patients with early-stage NSCLC with non-squamous histology have no available EGFR testing in the pre-ADAURA era. Of the anticipated 20% of patients with expected EGFR mutations based on historical controls, we have only identified half of patients that would have been eligible for adjuvant osimertinib. This study establishes the importance of upfront EGFR mutation testing in all NSCLC patients, not only to prognosticate, but also to identify the subset of patients who could benefit from adjuvant EGFR therapy.

Implementation Of EGFR Mutation Testing In Antwerp, Belgium: The HERMES-Project

2012 ◽  
Author(s):  
Paul Germonpre ◽  
Els De Droogh ◽  
Anneke Lefebure ◽  
Mark Kockx ◽  
Patrick Pauwels ◽  
...  
Keyword(s):  
Egfr Mutation ◽  
Mutation Testing ◽  
Egfr Mutation Testing

Population-based pan-Canadian EGFR-mutation testing program.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e18017-e18017 ◽  
Author(s):  
M. S. Tsao ◽  
D. Ionescu ◽  
G. Chong ◽  
A. M. Magliocco ◽  
D. Soulieres ◽  
...  
Keyword(s):  
Egfr Mutation ◽  
Population Based ◽  
Mutation Testing ◽  
Testing Program ◽  
Egfr Mutation Testing

Retrospective EGFR mutation testing of clinical specimens from the EURTAC trial of erlotinib in non-small cell lung cancer (NSCLC) using a novel allele-specific PCR (AS-PCR) assay.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10596-10596 ◽  
Author(s):  
Susana Benlloch ◽  
Miquel Taron ◽  
Maria Luisa Botero ◽  
Jordi Bertran-Alamillo ◽  
Clara Mayo ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Sanger Sequencing ◽  
Egfr Mutation ◽  
Mutation Testing ◽  
Pcr Assay ◽  
Percent Agreement ◽  
Egfr Mutant ◽  
Laser Capture ◽  
Egfr Mutation Testing ◽  
Exon 19

10596 Background: Anti-EGFR inhibitors are superior to chemotherapy in first-line therapy of advanced EGFR-mutant NSCLC. The EURTAC trial was a randomized Phase III trial of erlotinib vs. chemotherapy in patients with EGFR-mutant NSCLC. Interim results showed significant improvement in progression-free survival (R. Rosell, ASCO 2011). An accurate rapid in vitro diagnostic for EGFR mutations is needed to select patients for this therapy. Methods: Prospective EGFR mutation testing for the trial was performed on laser-capture microdissected tumor cells using a combination of 3 lab-developed tests (LDTs), including a Length Analysis of Fluorescently-labeled PCR (Genescan) method for exon 19 deletions, a Taqman-based PCR assay for exon 21 mutation with laser-capture macrodissected tumor cells, and secondary Sanger sequencing. A subset of samples from the trial was retrospectively tested with an AS-PCR assay (cobas EGFR mutation test) which detects L858R and > 29 exon 19 deletions. The test provides automated results within 8 h; the DNA required can be isolated from one 5-micron tissue section. Four methods were compared: AS-PCR assay, LDT, direct Sanger sequencing and massively parallel sequencing (MPS; 454, Branford, CT). Results: LDT results were obtained for 1044 screened patients. Residual tumor blocks were available for 487 patients (47%), including 303 wild-type, 172 mutant (135 enrolled on the trial) and 12 inconclusive cases by the LDT. Comparison of AS-PCR and LDT results showed a positive percent agreement (PPA) – 93.7% (CI 88.8%, 96.5%), and negative percent agreement (NPA) – 97.5% (94.9%, 98.8%). Comparison of AS-PCR and Sanger results showed a PPA of 96.6% (91.7%, 98.7%) but an NPA of 88.3% (84.1%, 91.5%). Among 34 AS-PCR+/Sanger- case, MPS confirmed the presence of exon 19 deletions in 25 cases and L858R mutations in 7. Direct comparison of AS-PCR and MPS results showed a PPA of 93.1% (88.1%, 96.1%) and NPA of 97.7% (95.0%, 98.9%). Clinical outcomes for cases with mutations detected by the AS-PCR test will be presented. Conclusions: The AS-PCR assay was highly concordant with the LDT and MPS, and more sensitive than Sanger sequencing.

Sign in / Sign up

Export Citation Format

Share Document